PE20161221A1 - Anticuerpos de il-21 - Google Patents

Anticuerpos de il-21

Info

Publication number
PE20161221A1
PE20161221A1 PE2016001575A PE2016001575A PE20161221A1 PE 20161221 A1 PE20161221 A1 PE 20161221A1 PE 2016001575 A PE2016001575 A PE 2016001575A PE 2016001575 A PE2016001575 A PE 2016001575A PE 20161221 A1 PE20161221 A1 PE 20161221A1
Authority
PE
Peru
Prior art keywords
seq
antibody
refers
sequence
amino acids
Prior art date
Application number
PE2016001575A
Other languages
English (en)
Inventor
Julian Davies
Fabio Magrini
Oliver Schroeder
Chetankumar Natvarlal Patel
Andrea Paula Martin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20161221A1 publication Critical patent/PE20161221A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a un anticuerpo que se une a IL-21 humana caracterizado porque comprende: a) una region variable de cadena pesada (HCVR) que comprende una secuencia de aminoacidos CDRH1, CDRH2 y CDRH3 de SEQ ID NO: 10, SEQ ID NO: 11 y SEQ ID NO: 12, respectivamente; y b) una region variable de cadena ligera (LCVR) que comprende una secuencia de aminoacidos CDRL1, CDRL2 y CDRL3 de SEQ ID NO: 7, SEQ ID NO: 8 y SEQ ID NO: 9. Tambien se refiere a su proceso de preparacion, a un metodo de tratamiento y a una composicion farmaceutica. Dicho anticuerpo tiene alta afinidad y neutralizan a IL-21 humana, siendo utiles en el tratamiento de enfermedades autoinmunes tal como lupus eritematoso sistemico, sindrome de Sjogren, diabetes tipo 1, entre otros
PE2016001575A 2014-03-21 2015-03-13 Anticuerpos de il-21 PE20161221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
PE20161221A1 true PE20161221A1 (es) 2016-11-12

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001575A PE20161221A1 (es) 2014-03-21 2015-03-13 Anticuerpos de il-21

Country Status (24)

Country Link
US (1) US9394362B2 (es)
EP (1) EP3119806B1 (es)
JP (2) JP6053989B2 (es)
KR (1) KR101859857B1 (es)
CN (1) CN106061999B (es)
AP (1) AP2016009450A0 (es)
AR (1) AR099625A1 (es)
AU (1) AU2015231777B2 (es)
BR (1) BR112016019176A2 (es)
CA (1) CA2939543C (es)
CL (1) CL2016002281A1 (es)
EA (1) EA033335B1 (es)
EC (1) ECSP16075416A (es)
ES (1) ES2774422T3 (es)
IL (1) IL246909A0 (es)
MA (1) MA39342B2 (es)
MX (1) MX2016012120A (es)
MY (1) MY177915A (es)
NZ (1) NZ722518A (es)
PE (1) PE20161221A1 (es)
PH (1) PH12016501820A1 (es)
SG (1) SG11201606705QA (es)
TW (1) TWI646105B (es)
WO (1) WO2015142637A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948275C (en) 2014-04-08 2023-10-17 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
EP3368090A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3436060A4 (en) * 2016-03-31 2019-12-04 Eli Lilly and Company ANTIBODIES AGAINST IL-21 AND USES THEREOF
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309238A1 (en) * 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3226365A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
RU2504552C2 (ru) * 2007-12-07 2014-01-20 Займодженетикс, Инк. Моноклональные антитела против il-21 человека
HUE036548T2 (hu) * 2007-12-07 2018-08-28 Zymogenetics Inc IL-31-re specifikus humanizált antitest molekulák
JP2014506259A (ja) 2011-01-17 2014-03-13 ノヴォ ノルディスク アー／エス Ｉｌ−２１リガンド
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
US9394362B2 (en) 2016-07-19
JP6373944B2 (ja) 2018-08-15
MA39342B2 (fr) 2020-03-31
JP2017093435A (ja) 2017-06-01
PH12016501820A1 (en) 2016-11-07
KR20160124166A (ko) 2016-10-26
CN106061999A (zh) 2016-10-26
MX2016012120A (es) 2016-12-09
MA39342A1 (fr) 2018-03-30
AU2015231777A1 (en) 2016-08-18
ES2774422T3 (es) 2020-07-21
TWI646105B (zh) 2019-01-01
JP2016520088A (ja) 2016-07-11
CL2016002281A1 (es) 2017-06-23
EA201691521A1 (ru) 2017-02-28
TW201623330A (zh) 2016-07-01
ECSP16075416A (es) 2018-05-31
MY177915A (en) 2020-09-25
BR112016019176A2 (pt) 2017-10-10
JP6053989B2 (ja) 2017-01-11
AP2016009450A0 (en) 2016-09-30
EP3119806A1 (en) 2017-01-25
CA2939543C (en) 2018-01-16
KR101859857B1 (ko) 2018-05-18
US20150266954A1 (en) 2015-09-24
EA033335B1 (ru) 2019-09-30
IL246909A0 (en) 2016-09-29
EP3119806A4 (en) 2017-11-01
AR099625A1 (es) 2016-08-03
WO2015142637A1 (en) 2015-09-24
CN106061999B (zh) 2020-07-31
AU2015231777B2 (en) 2017-08-03
EP3119806B1 (en) 2020-01-01
SG11201606705QA (en) 2016-09-29
CA2939543A1 (en) 2015-09-24
NZ722518A (en) 2017-12-22

Similar Documents

Publication Publication Date Title
PE20161221A1 (es) Anticuerpos de il-21
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
CO2018004532A2 (es) Anticuerpos anti-cd19 humano con alta afinidad
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
JP2020500538A5 (es)
BR112019011988A2 (pt) anticorpo anti-cd73 humana
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20180120A1 (es) Proteinas de union a icos
PE20161439A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
PE20161033A1 (es) Proteinas de union al antigeno gitr
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
AR086044A1 (es) Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
AR109715A1 (es) Anticuerpos anti-cd27
PE20170687A1 (es) Proteinas de enlace a cd127
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
AR102594A1 (es) ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO
AR086579A1 (es) Proteinas de union a antigeno